Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Coya Therapeutics, Inc. Common Stock (COYA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: COYA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $16.75
1 Year Target Price $16.75
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.43% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 97.84M USD | Price to earnings Ratio - | 1Y Target Price 16.75 |
Price to earnings Ratio - | 1Y Target Price 16.75 | ||
Volume (30-day avg) 5 | Beta 0.21 | 52 Weeks Range 4.65 - 10.24 | Updated Date 06/29/2025 |
52 Weeks Range 4.65 - 10.24 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.07 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2976.89% |
Management Effectiveness
Return on Assets (TTM) -32.06% | Return on Equity (TTM) -52.11% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 62310614 | Price to Sales(TTM) 26.55 |
Enterprise Value 62310614 | Price to Sales(TTM) 26.55 | ||
Enterprise Value to Revenue 16.91 | Enterprise Value to EBITDA -6.21 | Shares Outstanding 16725000 | Shares Floating 12571345 |
Shares Outstanding 16725000 | Shares Floating 12571345 | ||
Percent Insiders 7.02 | Percent Institutions 28.07 |
Analyst Ratings
Rating 3 | Target Price 16.75 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Coya Therapeutics, Inc. Common Stock
Company Overview
History and Background
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing innovative therapies for neurodegenerative diseases, with an emphasis on regulatory T cells (Tregs). Founded to address unmet needs in these areas, Coya has built a platform centered on Treg biology.
Core Business Areas
- Treg-based Therapies: Focuses on developing therapies based on the immunomodulatory properties of Tregs for the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).
- Pipeline Development: Engages in preclinical and clinical research to expand its pipeline of Treg-modulating therapies targeting various neurodegenerative and autoimmune diseases.
Leadership and Structure
Coya Therapeutics is led by a management team with experience in immunology and drug development. The organizational structure includes research, clinical development, and business operations departments.
Top Products and Market Share
Key Offerings
- COYA 101: An autologous Treg cell therapy being investigated for the treatment of ALS. The market share and revenue from this product is not available yet as the product is in clinical trials. Competitors include Biogen (Tofersen), Amylyx Pharmaceuticals (Relyvrio) and numerous other companies pursuing ALS treatments.
- COYA 206: A biologic product designed to enhance Treg function, currently in preclinical development targeting neurodegenerative diseases. Competitors for this unreleased product are varied and highly dependent on the final indication.
Market Dynamics
Industry Overview
The biotechnology industry focused on neurodegenerative diseases is characterized by high unmet needs and significant research activity. The market is competitive with numerous companies developing novel therapies.
Positioning
Coya Therapeutics is positioned as a company specializing in Treg-based therapies for neurodegenerative diseases. Its competitive advantage lies in its focus on Treg biology and its potential to address the underlying immune dysfunction in these conditions.
Total Addressable Market (TAM)
The TAM for ALS and other neurodegenerative diseases is significant, projected to reach billions of dollars. Coya's position within this TAM is dependent on the success of its clinical trials and subsequent commercialization efforts.
Upturn SWOT Analysis
Strengths
- Proprietary Treg platform
- Focus on neurodegenerative diseases with high unmet needs
- Experienced management team
- Promising early clinical data
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Relatively small company size
- Single therapeutic focus
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to other autoimmune diseases
- Positive clinical trial results leading to accelerated approval
- Increasing awareness of Treg-based therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- BIIB
- AMLY
Competitive Landscape
Coya Therapeutics faces competition from established pharmaceutical companies with greater resources and broader pipelines. Its competitive advantage lies in its specialized Treg platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and early clinical development activities. Growth is tied to achieving clinical milestones.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization. Analyst projections, if available, are highly speculative.
Recent Initiatives: Recent initiatives include advancing clinical trials for COYA 101 and progressing preclinical development for COYA 206.
Summary
Coya Therapeutics is a clinical-stage biotech focused on Treg therapies for neurodegenerative diseases. Its success hinges on positive clinical trial outcomes. The company's small size and limited resources pose challenges, while successful trials could lead to significant opportunities. Investors should closely monitor clinical trial results and financial runway.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports (where available)
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Data is based on publicly available information and may not be entirely accurate or complete. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coya Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2022-12-29 | CEO & Director Dr. Arun Swaminathan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://coyatherapeutics.com |
Full time employees 8 | Website https://coyatherapeutics.com | ||
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, the company's pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.